RDY Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Dr. Reddy's Laboratories (NYSE: RDY)
›
Dr. Reddy's Laboratories (NYSE: RDY) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 27,527 employees.
The shares were at 14.83 USD on 19 November 2026, up 6.5% over 52 weeks. Its 52-week range is 11.36 USD to 15.67 USD: the price is 5.4% below the high and 30.5% above the low.
At a market capitalisation of 12.36B USD, it trades at 41.2 times trailing earnings and 22.4 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 67% for RDY. It pays a dividend yielding 0.56% (it pays out 23% of its earnings), against a median of 2.01% among the dividend payers in that peer group.
Dr. Reddy's Laboratories reports return on equity of 11.4%, an operating margin of 9.1% and revenue down 1.5% year over year.
It holds more cash than debt, a net cash position of 3.95B INR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 14.82 USD is 0.1% below the current price. The next earnings report is expected on 21 January 2027.